Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 4 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
6 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.

20-year study confirms safety of vaccines

05 Aug 2020

Vaccines have been shown to be “remarkably safe” over a 20-year period, reveals a US study.

Several safety issues have been identified via existing postmarketing surveillance programmes and are of limited clinical significance, according to the authors.

Initial and subsequent labels of all vaccines approved by the Food and Drug Administration (FDA) between 1 January 1996 and 31 December 2015 were included in this retrospective cohort study. The authors performed a descriptive analysis of the prevalence and characteristics of postapproval, safety-related label changes, and described the distribution of data sources triggering these modifications.

Fifty-seven FDA-approved vaccines were analysed, of which 53 (93 percent) had initial approval supported by randomized controlled trials, with a median cohort size of 4,161 participants (interquartile range, 2,204–8,634). Fifty-eight postapproval, safety-related label modifications were associated with 25 vaccines (49 warnings and precautions, eight contraindications, and one safety-related withdrawal).

The initial approval trial characteristics were similar in vaccines with and without postmarketing, safety-related label modifications. Expansion of populations restrictions (n=21, 36 percent) was the most common safety issue prompting label modifications, followed by allergies (n=13, 22 percent). Moreover, postmarketing surveillance (n=28 of 58, 48 percent) was the most common source of safety data.

“These findings confirm the robustness of the vaccine approval system and postmarketing surveillance,” the authors said.

With regard to the limitations of this study, all safety data received and processed by the FDA were not necessarily represented by the data sources of the initial signal triggering safety-related label changes, according to the authors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 4 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
6 days ago
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
Audrey Abella, 11 Sep 2020
A prasugrel de-escalation strategy significantly reduced the risk of NACE* and bleeding events in patients with ACS** after PCI*** compared with the conventional strategy, results of the HOST-REDUCE-POLYTECH-ACS# trial have shown.